ASX Health Stocks: These three ASX biotechs get to strut their stuff with Bell Potter and Nature Portfolio

The Bell Potter Healthcare Conference will showcase small and mid-cap healthcare stocks
Starpharma and Artrya are scheduled to present at the conference
HeraMED’s clinical trial results published in Nature Portfolio journal

A difficult global macroeconomic environment has taken its toll on global equity markets in 2022, with growth oriented stocks feeling the brunt of investor sentiment.

Small to mid cap healthcare stocks have generally been subject to significant valuation corrections. Yet despite these challenges, the need for innovative solutions to treat disease remains.

The Bell Potter Healthcare Conference, showcasing Australasia’s small and mid-cap healthcare offering, is a three-day conference starting today.

ASX-listed Starpharma (ASX:SPL) will present at the conference. Its dendrimer technology plays a starring role in its marketed products, VIRALEZE nasal spray and VivaGel.

VIRALEZE is a broad-spectrum nasal spray developed in response to the Covid-19 outbreak in 2020, to trap and block respiratory viruses in the nasal cavity.

Starpharma has worked tirelessly to get VIRALEZE registered in more than 30 countries, and today it is available from a variety of retail outlets and pharmacies around the world, as well as online.

The company has already secured partnerships with several of the world’s largest pharmaceutical companies, including a multiproduct licence with AstraZeneca and research collaborations with Merck & Co. and Genentech.

Artrya (ASX:AYA) will also present at the Bell Potter Conference. It develops software which automates the analysis of heart computed tomography (CT) scans to assist in the diagnosis of Coronary Artery Disease.

Its Salix technology is an AI-based solution which analyses cardiac CT scans to detect heart attack biomarkers, and produces a comprehensive patient report in just 15 minutes.

Market pilots of Salix are underway in Australia, and the company expects a number of these pilot programs to progress to commercial use this year.

This week, Artya announced a regulatory approval for its Salix Coronary Anatomy (SCA) product in the United Kingdom.

The European Notified Body (BSI) has notified Artrya that the assessment for UKCA Class 2 Certification has been completed and it will recommend certification of the Salix V2.0 Software for marketing into the UK.

Meanwhile, medical data company HeraMED (ASX:HMD) announced the publication of the second Clinical Trial by Joondalup Health Campus in Nature Portfolio, part of Nature.com.

The Clinical Trial results were published on ASX on 2 May, which outlined the results from the second JHC clinical trial to validate HeraBEAT as a full CTG (cardiotography) monitor.

Those results have further validated HeraBEAT’s superiority for extended, CTG equivalent remote and home monitoring of FHR (Foetal Heart Rate).